A successful shortening of desensitization protocol in a patient with cetuximab anaphylaxis-Reference-Cited by-同舟云学术

A successful shortening of desensitization protocol in a patient with cetuximab anaphylaxis

Published:2022 Issue:3 Volume:10 Page:181
ISSN:2288-0402
Container-title:Allergy, Asthma & Respiratory Disease
language:ko
Short-container-title:Allergy Asthma Respir Dis

Author:

Seo Jang Ho¹²,Jung Jiung¹,Yoon Jeong Eun¹,Kim Hyun Hwa²,Kim Hyun Ji²,Lee Suh Young¹²,Kang Hye-Ryun¹²³^ORCID

Affiliation:

1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

2. Drug safety Center, Seoul National University Hospital, Seoul, Korea.

3. Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul National University College of Medicine, Seoul, Korea.

Funder

Ministry of Food and Drug Safety

Publisher

The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al

Subject

General Medicine

Link

https://aard.or.kr/pdf/10.4168/aard.2022.10.3.181

Reference20 articles.

1. The Role of Cetuximab in the Management of Non–Small-Cell Lung Cancer

2. Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies

3. Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

4. Successful rapid desensitization for cetuximab-induced anaphylaxis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What is New in Alpha-Gal Syndrome?;Current Treatment Options in Allergy;2023-11-22

2. Desensitization for the prevention of drug hypersensitivity;Allergy, Asthma & Respiratory Disease;2023